The clinical trial report, “Diffuse Large B-Cell Lymphoma - Global Clinical Trials Review, 2026" provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma
- Mar 22, 2026: HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in China
- Mar 10, 2026: Imugene Reports 100% & 80% Overall Response Rate in Subset Indications in azer-cel Phase 1b study
- Mar 06, 2026: Elicera Therapeutics Reports CMR and Well Tolerated Treatment in First Two Patients of Cohort 3 in Carma Study, Bringing CMR to 6 Out of 8 Patients
- Mar 04, 2026: Citius Oncology Announces Topline Phase 1 Data from Study of E7777 Dosing Prior to Commercial CAR-T Therapy in High-Risk DLBCL
- Feb 13, 2026: Lyell doses first patient in Phase III trial for LBCL
- Feb 05, 2026: Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288
- Jan 29, 2026: MT-2111 Achieved Primary Endpoint in Phase 2 part of Japanese Phase 1/2 study for Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Jan 19, 2026: Genmab reports top line results in Phase III DLBCL trial
- Jan 06, 2026: Incyte reports positive data from tafasitamab Phase III trial for DLBCL
- Clinical Trial Profile Snapshots
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Disclaimer
- Source
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2025-2021
- Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2025-2021
- Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Bristol-Myers Squibb Co
- Roche Holding AG
- AbbVie Inc
- Gilead Sciences Inc
- AstraZeneca Plc
- Novartis AG
- Thermo Fisher Scientific Inc
- Pfizer Inc
- Johnson & Johnson
- Merck & Co Inc
